Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Accumulated Expenses for 18 consecutive years, with $1.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 19.26% year-over-year to $1.1 billion; the trailing twelve-month figure through Jun 2026 stood at $1.1 billion (up 19.26% YoY), and the FY2025 full-year result was $1.1 billion, up 36.1% from the prior year.
• Accumulated Expenses climbed to $1.1 billion in Q2 2026 per ALNY's latest filing, from $946.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $1.2 billion in Q3 2025 and bottomed at $355.9 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $750.7 million across 5 years, with a median of $713.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses surged 42.89% in 2023, then climbed 0.76% in 2025.
• Over 5 years, Accumulated Expenses stood at $545.5 million in 2022, then jumped by 30.72% to $713.0 million in 2023, then rose by 11.32% to $793.7 million in 2024, then surged by 36.1% to $1.1 billion in 2025, then grew by 1.46% to $1.1 billion in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.1 billion, $946.5 million, and $1.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.